640×0-2

Teva Pharmaceuticals CFO Eyal Desheh, second left, Chairman Dr. Phillip Frost, third left, and CEO Jeremy Levin, fourth left, applaud during opening bell ceremonies of the New York Stock Exchange Wednesday, May 30, 2012. The Israeli company said last week it expects weaker sales of generic drugs, which bring in most of its revenue, and of brand-name products, which has become a priority for Teva in recent years and drove its recent $6.8 billion acquisition of Cephalon Inc. (AP Photo/Richard Drew)

Leave a Comment